| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3405440 | Journal des Anti-infectieux | 2015 | 11 Pages |
Abstract
Moxifloxacin or rifapentine-based short course regimens in association with first line drugs for drug-sensitive tuberculosis results in high relapse rates and should nowadays not be preferred to the standard 6Â months regimen. Further trials that explore short course of new antituberculosis drugs associations are needed for either drug-sensitive or resistant tuberculosis.
Related Topics
Health Sciences
Medicine and Dentistry
Infectious Diseases
Authors
D. Le Dû,